Yeast-Based Aβ1-15 Vaccine Elicits Strong Immunogenicity and Attenuates Neuropathology and Cognitive Deficits in Alzheimer’s Disease Transgenic Mice
Immunotherapy focusing on reducing the amyloid-beta (Aβ) burden is a promising treatment strategy for Alzheimer’s disease (AD). Many clinical studies on AD immunotherapies have failed due to low safety and efficacy, calling for a highly potent AD vaccine which induces sufficient antibody titer while...
Main Authors: | Dong-qun Liu, Shuai Lu, Lun Zhang, Ya-ru Huang, Mei Ji, Xiao-ying Sun, Xiao-ge Liu, Rui-tian Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-07-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/8/3/351 |
Similar Items
-
Naringin Dihydrochalcone Ameliorates Cognitive Deficits and Neuropathology in APP/PS1 Transgenic Mice
by: Wenjuan Yang, et al.
Published: (2018-06-01) -
Indirubin-3'-monoxime rescues spatial memory deficits and attenuates β-amyloid-associated neuropathology in a mouse model of Alzheimer's disease
by: Yun Ding, et al.
Published: (2010-08-01) -
A vaccine with Aβ oligomer-specific mimotope attenuates cognitive deficits and brain pathologies in transgenic mice with Alzheimer’s disease
by: Shao-wei Wang, et al.
Published: (2017-06-01) -
Yeast Models for the Study of Amyloid-Associated Disorders and Development of Future Therapy
by: Sigal Rencus-Lazar, et al.
Published: (2019-03-01) -
Modeling of molecular processes underlying Parkinson’s disease in cells of methylotrophic yeast Hansenula polymorpha
by: I. O. Denega, et al.
Published: (2014-09-01)